Is Anticonvulsant Treatment of Mania a Class Effect? Data from Randomized Clinical Trials

CNS Neuroscience and Therapeutics

Volumn 17, Issue 3, 2011, Pages 167-177

  Rosa, A R ^a   Fountoulakis, K ^b   Siamouli, M ^b   Gonda, X ^c   Vieta, E ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Acute mania; Anticonvulsants; Antiepileptics; Bipolar disorder; Clinical trials; Randomized placebo controlled; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETIRACETAM; FELBAMATE; GABAPENTIN; HALOPERIDOL; LAMOTRIGINE; LICARBAZEPINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PHENYTOIN; PLACEBO; PREGABALIN; QUETIAPINE; RETIGABINE; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ACUTE DISEASE; AGRANULOCYTOSIS; ANXIETY DISORDER; APLASTIC ANEMIA; ATAXIA; BIPOLAR DISORDER; BIPOLAR MANIA; COMORBIDITY; CONGENITAL MALFORMATION; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HYPOMANIA; HYPONATREMIA; LEUKOPENIA; MANIA; META ANALYSIS; MONOTHERAPY; NAUSEA; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SIDE EFFECT; SKIN DISEASE; SOMNOLENCE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AMINES; ANTICONVULSANTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LITHIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRIAZINES; VALPROIC ACID;

EID: 79955746700     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00089.x     Document Type: Review

References (65)

1. Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, Fresno D, Giannakopoulos P, Kaprinis GS. Treatment of bipolar disorder: A complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007;6:27.
2. Hirschfeld RMA, Keck CPE, Gitlin MJ, Price LH, Sajatovic M, Suples M, Thase ME, Perlis RH. Practice Guideline for the treatment of patients with bipolar disorder. Third Edition, Am J Psychiatry, in press.
3. Bowden CL, Karren NU. Anticonvulsants in bipolar disorder. Aust N Z J Psychiatry 2006;40:386-393.
4. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: A systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol 2008;11:999-1029.
5. Vieta E, Sugranyes G, Goikolea JM. New anticonvulsants in bipolar disorder: All that glisters is not gold. Adv Schizophr Clin Psychitray 2008;4:106-113.
6. Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci 2008;10:165-179.
7. Lehman AF, Steinwachs DM. Translating research into practice: The Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998;24:1-10.
8. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht R, Vieta E, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression. World J Biol Psychiatry 2002;3:115-124.
9. Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, Vieta E, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of mania. World J Biol Psychiatry 2003;4:5-13.
10. Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: Maintenance treatment. World J Biol Psychiatry 2004;5:120-135.
11. Bech P. The Bech-Rafaelsen Mania Scale in clinical trials of therapies for bipolar disorder: A 20-year review of its use as an outcome measure. CNS Drugs 2002;16:47-63.
12. Cipriani A, Rendell JM, Geddes JR. Haloperidol alone or in combination for acutemania. Cochrane Database Syst Rev 2006;3:CD004362.
13. Davis JM, Janicak PG, Hogan DM. Mood stabilizers in the prevention of recurrent affective disorders: A meta-analysis. Acta Psychiatr Scand 1999;100:406-417.
14. Macritchie K, Geddes JR, Scott J, Haslam D, de Lima M, Goodwin G. Valproate foracute mood episodes in bipolar disorder. Cochrane Database Syst Rev 2003;CD004052.
15. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001;CD003196.
16. Rendell JM, Gijsman HJ, Keck P, Goodwin GM, Geddes JR. Olanzapine alone or incombination for acute mania. Cochrane Database Syst Rev 2003;CD004040.
17. Rendell JM, Gijsman HJ, Bauer MS, Goodwin GM, Geddes GR. Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006;CD004043.
18. Smith LA, Cornelius V, Warnock A, Tacchi MJ, Taylor D. Acute bipolar mania: A systematic review and meta-analysis of co-therapy vs. monotherapy. Acta Psychiatr Scand 2007;115:12-20.
19. Emrich HM, von Zerssen D, Kissling W, Möller HJ. Therapeutic effect of valproate in mania. Am J Psychiatry 1981;138:256.
20. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in the treatment of acute mania. A placebo-controlled study. Arch Gen Psychiatry 1991;48:62-68.
21. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA 1994;271:918-924.
22. Bowden CL, Swann AC, Calabrese JR, Rubenfaer LM, Wozniak PJ, Collins MA, Abi Saab W, Saltarelli M. A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry 2006;67:1501-1510.
23. Emrich HM, von Zerssen D, Kissling W, Möller HJ, Windorfer A. Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980;229:1-16.
24. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small J, Dilsaver SC, Davis JM. Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997;54:37-42.
25. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999;156:1264-1266.
26. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry 1992;149:108-111.
27. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl) 2000;150:15-23.
28. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry 1996;57:142-146.
29. Hirschfeld RM, Allen MH, McEvoy JP, Keck PE Jr, Russell JM. Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. J Clin Psychiatry 1999;60:815-818.
30. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-1017.
31. Zajecka JM, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63:1148-1155.
32. DelBello MP, Kowatch RA, Adler CM, Stanford KE, Welge JA, Barzman DH, Nelson E, Strakowski SM. A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania. J Am Acad Child Adolesc Psychiatry 2006;45:305-313.
33. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000;20:195-203.
34. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583.
35. Bowden CL. Valproate. Bipolar Disord 2003;5:189-202.
36. Nasrallah HA, Ketter TA, Kalali AH. Carbamazepine and valproate for the treatment of bipolar disorder: A review of the literature. J Affect Disord 2006;95:69-78.
37. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry 1980;137:782-790.
38. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004;65:478-484.
39. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005;66:323-330.
40. Weisler RH, Hirschfeld R, Cutler AJ, Gazda T, Ketter TA, Keck PE, Swann A, Kalali A. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: Pooled results from two randomised, double-blind, placebo-controlled trials. CNS Drugs 2006;20:219-231.
41. Tohen M, Bowden CL, Smulevich AB, et al. Olanzapine plus carbamazepine v. carbamazepine alone in treating manic episodes. Br J Psychiatry 2008;192:135-143.
42. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry 2003;182:141-147.
43. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine versus lithium in mania: A double-blind study. J Clin Psychiatry 1987;48:89-93.
44. Small JG, Klapper MH, Milstein V, Kellams JJ, Miller MJ, Marhenke JD, Small IF. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991;48:915-921.
45. Okuma T, Yamashita I, Takahashi R, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990;23:143-150.
46. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology (Berl) 1979;66:211-217.
47. Brown D, Silverstone T, Cookson JD. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 1989;4:229-238.
48. Small JG, Klapper MH, Marhenke JD, Milstein V, Woodham GC, Kellams J. Lithium combined with carbamazepine or haloperidol in the treatment of mania. Psychopharmacol Bull 1995;31:265-272.
49. Stoner SC, Nelson LA, Lea JW, Marken PA, Sommi RW, Dahmen MM. Historical review of carbamazepine for the treatment of bipolar disorder. Pharmacotherapy 2007;27:68-88.
50. Flanagan RJ, Dunk L. Hematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23(Suppl 1):27-41.
51. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006;163:1179-1186.
52. Ghaemi NS, Arshia A, Shirzadi DO, Filkowoki M. Publication bias and the pharmaceutical industry: The case of lamotrigine in bipolar disorder. Medscape J Med 2008;10:211.
53. Anand A, Oren DA, Bernan RM. Lamotrigine treatment lithium failure in outpatients mania: A double-blind, placebo controlled trial. In: Soares JC, Gershon S, editors. (Abstract book), Third international bipolar conference, Pithsburg Munksgaard, 1999; 23.
54. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, Luckenbaugh DA, Cora-Ocatelli G, Leverich GS, Post RM. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000;20:607-614.
55. Ichim L, Berk M, Brook S. Lamotrigine compared with lithium in mania: A double-blind randomized controlled trial. Ann Clin Psychiatry 2000;12:5-10.
56. Yatham LN, Kusumakar V, Calabrese JR, Rao R, Scarrow G, Kroeker G. Third generation anticonvulsants in bipolar disorder: A review of efficacy and summary of clinical recommendations. J Clin Psychiatry 2002;63:275-83.
57. Pande AC, Crockatt JG, Janney CA, Werth JL, Tsaroucha G. Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000;2:249-255.
58. Mokhber N, Lane CJ, Azarpazhooh MR, Salari E, Fayazi R, Shakeri MT, Young AH. Anticonvulsivant treatments of dysphoric mania: A trial of gabapentin, lamotrigin and carbamazepine in Iran. Neuropsychiatr Dis Treat 2008;41:227-234.
59. Kushner SF, Khan A, Lane R, Olson WH. Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord 2006;8:15-27.
60. Vieta E, Sánchez-Moreno J, Goikolea JM, Torrent C, Benabarre A, Colom F, Martínez-Arán A, Reinares M, Comes M, Corbella B. Adjunctive topiramate in bipolar II disorder. World J Biol Psychiatry 2003;4:172-176.
61. Chengappa KN, Schwarzman LK, Hulihan JF, Xiang J, Rosenthal NR. Clinical Affairs Product Support Study-168 Investigators. Adjunctive topiramate therapy in patients receiving a mood stabilizer for bipolar I disorder: A randomized, placebo-controlled trial. J Clin Psychiatry 2006;67:1698-1706.
62. Mishory A, Yaroslavsky Y, Bersudsky Y, Belmaker RH. Phenytoin as an antimanic anticonvulsant: A controlled study. Am J Psychiatry 2000;157:463-465.
63. Vieta E, Rosa AR. Evolving trends in the long-term treatment of bipolar disorder. World J Biol Psychiatry 2007;8:4-11.
64. Amann B, Grunze H, Vieta E, Trimble M. Antiepileptic drugs and mood stability. Clin EEG Neurosci 2007;38:116-123.
65. Isojärvi JI, Airaksinen KE, Repo M, Pakarinen AJ, Salmela P, Myllylä VV. Carbamazepine, serum thyroid hormones and myocardial function in epileptic patients. J Neurol Neurosurg Psychiatry 1993;56:710-712.